Epidemiology, biology and therapy of Merkel cell carcinoma: conclusions from the EU project IMMOMEC

November 30, 2017


Cancer Immunology, Immunotherapy

Publication Date

November 30, 2017


Becker J, Stang A, Hausen A, Fischer N, DeCaprio J, Tothill R, Lyngaa R, Hansen U, Ritter C, Bichakjian C, Ugurel S, Schrama D, Nghiem P

Download PDF


Merkel cell carcinoma (MCC) is a highly aggressive, often lethal neuroendocrine cancer. Its carcinogenesis may be either caused by the clonal integration of the Merkel cell polyomavirus into the host genome or by UV-induced mutations. Notably, virally-encoded oncoproteins and UV-induced mutations affect comparable signaling pathways such as RB restriction of cell cycle progression or p53 inactivation. Despite its low incidence, MCC recently received much attention based on its exquisite immunogenicity and the resulting major success of immune modulating therapies. Here, we summarize current knowledge on epidemiology, biology and therapy of MCC as conclusion of the project ‘Immune Modulating strategies for treatment of Merkel Cell Carcinoma’, which was funded over a 5-year period by the European Commission to investigate innovative immunotherapies for MCC.

View the clinical publication